Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment Neuropsychiatric Disease and Treatment
暂无分享,去创建一个
[1] C. Correll,et al. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities , 2019, CNS Spectrums.
[2] Anissa Abi-Dargham,et al. Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms , 2019, Trends in Neurosciences.
[3] C. Correll,et al. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses , 2018, Therapeutic advances in psychopharmacology.
[4] M. Cannon,et al. Negative symptoms of psychosis: A life course approach and implications for prevention and treatment , 2018, Early intervention in psychiatry.
[5] S. Galderisi,et al. Negative symptoms of schizophrenia: new developments and unanswered research questions. , 2018, The lancet. Psychiatry.
[6] C. Correll,et al. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia , 2018, Acta psychiatrica Scandinavica.
[7] S. Leucht,et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis , 2018, European Archives of Psychiatry and Clinical Neuroscience.
[8] S. Stahl. Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes , 2017, CNS Spectrums.
[9] I. Melle,et al. Treatment of negative symptoms: Where do we stand, and where do we go? , 2017, Schizophrenia Research.
[10] R. Luthringer,et al. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. , 2017, The American journal of psychiatry.
[11] C. Correll,et al. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence , 2017, JAMA psychiatry.
[12] V. Sohal,et al. D3 Receptors Regulate Excitability in a Unique Class of Prefrontal Pyramidal Cells , 2017, The Journal of Neuroscience.
[13] J. Geddes,et al. 60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis and meta-regression of efficacy predictors , 2017 .
[14] B. Kiss,et al. Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model , 2017, The international journal of neuropsychopharmacology.
[15] P. Czobor,et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial , 2017, The Lancet.
[16] S. Galderisi,et al. The current conceptualization of negative symptoms in schizophrenia , 2017, World psychiatry : official journal of the World Psychiatric Association.
[17] P. Sokoloff,et al. The dopamine D3 receptor, a quarter century later , 2017, The European journal of neuroscience.
[18] S. Leucht,et al. Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. , 2016, The American journal of psychiatry.
[19] H. Häfner,et al. Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia , 2016, European Archives of Psychiatry and Clinical Neuroscience.
[20] S. Schulz,et al. Dopamine D3 Receptors Inhibit Hippocampal Gamma Oscillations by Disturbing CA3 Pyramidal Cell Firing Synchrony , 2016, Front. Pharmacol..
[21] J. Azorin,et al. [Negative symptoms of schizophrenia: from electrophysiology to electrotherapy]. , 2015, L'Encephale.
[22] J. Torous,et al. Smartphone Apps for Schizophrenia: A Systematic Review , 2015, JMIR mHealth and uHealth.
[23] E. Budtz-Jørgensen,et al. Long-term trajectories of positive and negative symptoms in first episode psychosis: A 10year follow-up study in the OPUS cohort , 2015, Schizophrenia Research.
[24] P. McGuire,et al. Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. , 2015, Schizophrenia bulletin.
[25] J. Mintz,et al. A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia , 2015, Schizophrenia Research.
[26] H. Möller,et al. Pharmacological treatment of negative symptoms in schizophrenia , 2015, European Archives of Psychiatry and Clinical Neuroscience.
[27] C. Correll,et al. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia , 2014, CNS Spectrums.
[28] P. Chue,et al. Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options , 2014, Neuropsychiatric disease and treatment.
[29] G. Remington,et al. Negative symptoms of schizophrenia: Clinical features, relevance to real world functioning and specificity versus other CNS disorders , 2014, European Neuropsychopharmacology.
[30] Thomas Steckler,et al. Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment , 2014, European Neuropsychopharmacology.
[31] W. Gaebel,et al. Negative symptoms, past and present: A historical perspective and moving to DSM-5 , 2014, European Neuropsychopharmacology.
[32] M. Clarke,et al. Do psychosis prodrome onset negative symptoms predict first presentation negative symptoms? , 2014, European Psychiatry.
[33] D. Velligan,et al. Integrated Psychosocial Treatment for Negative Symptoms , 2014 .
[34] A. Kring,et al. Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions. , 2013, Clinical psychology review.
[35] S. Salomone,et al. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. , 2013, European journal of pharmacology.
[36] S. Kapur,et al. Negative symptoms in schizophrenia – the remarkable impact of inclusion definitions in clinical trials and their consequences , 2013, Schizophrenia Research.
[37] S. Marder,et al. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: A CATIE analysis , 2013, Schizophrenia Research.
[38] S. Marder,et al. Pharmacological approaches to treating negative symptoms: A review of clinical trials , 2013, Schizophrenia Research.
[39] D. Daniel. Issues in Selection of Instruments to Measure Negative Symptoms , 2013, Schizophrenia Research.
[40] S. Scuderi,et al. Increased Hippocampal CREB Phosphorylation in Dopamine D3 Receptor Knockout Mice Following Passive Avoidance Conditioning , 2013, Neurochemical Research.
[41] B. Kiss,et al. Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse , 2013, Psychopharmacology.
[42] C. Correll. The Prevalence of Negative Symptoms in Schizophrenia and Their Impact on Patient Functioning and Course of Illness , 2013 .
[43] R. Gur,et al. The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. , 2013, The American journal of psychiatry.
[44] J. Coyle. NMDA receptor and schizophrenia: a brief history. , 2012, Schizophrenia bulletin.
[45] Philip D. Harvey,et al. Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status , 2012, World psychiatry : official journal of the World Psychiatric Association.
[46] John M. Davis,et al. Maintenance treatment with antipsychotic drugs for schizophrenia. , 2012, The Cochrane database of systematic reviews.
[47] Tyrone D. Cannon,et al. Negative symptoms in individuals at clinical high risk of psychosis , 2012, Psychiatry Research.
[48] M. Millan,et al. Selective Blockade of Dopamine D3 Receptors Enhances while D2 Receptor Antagonism Impairs Social Novelty Discrimination and Novel Object Recognition in Rats: A Key Role for the Prefrontal Cortex , 2012, Neuropsychopharmacology.
[49] F. Chacón,et al. Efficacy of lifestyle interventions in physical health management of patients with severe mental illness , 2011, Annals of general psychiatry.
[50] W. Wölwer,et al. Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomized clinical TONES study. , 2011, Schizophrenia bulletin.
[51] E. Walker,et al. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[52] Vyv Huddy,et al. A Meta-Analysis of Cognitive Remediation for Schizophrenia: Methodology and Effect Sizes , 2012 .
[53] S. Marder,et al. The brief negative symptom scale: psychometric properties. , 2011, Schizophrenia bulletin.
[54] T. Barnes. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology , 2011, Journal of psychopharmacology.
[55] Daniel Antonius,et al. Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. , 2011, Clinical psychology review.
[56] Kyeong-Man Kim,et al. Current perspectives on the selective regulation of dopamine D2 and D3 receptors , 2010, Archives of pharmacal research.
[57] L. Alphs,et al. The 4-Item Negative Symptom Assessment (NSA-4) Instrument: A Simple Tool for Evaluating Negative Symptoms in Schizophrenia Following Brief Training. , 2010, Psychiatry (Edgmont (Pa. : Township)).
[58] Jonathan Y. Tsou. RACHEL COOPER Classifying Madness: A Philosophical Examination of the Diagnostic and Statistical Manual of Mental Disorders , 2010, The British Journal for the Philosophy of Science.
[59] J. Bobes,et al. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. , 2010, The Journal of clinical psychiatry.
[60] Gary Remington,et al. Negative symptoms in schizophrenia: avolition and Occam's razor. , 2010, Schizophrenia bulletin.
[61] D. Linszen,et al. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis , 2009, Schizophrenia Research.
[62] S. Leucht,et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials , 2009, Molecular Psychiatry.
[63] P. Gorwood. Neurobiological mechanisms of anhedonia , 2008, Dialogues in clinical neuroscience.
[64] B. Kiss,et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15 , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.
[65] S. Stahl,et al. Stahl's essential psychopharmacology : neuroscientific basis and practical application , 2008 .
[66] M Isohanni,et al. Negative symptoms in schizophrenia—A review , 2008, Nordic journal of psychiatry.
[67] D. Javitt,et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. , 2007, The American journal of psychiatry.
[68] R. Buchanan,et al. Persistent negative symptoms in schizophrenia: an overview. , 2007, Schizophrenia bulletin.
[69] J. Coyle,et al. Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis , 2006, Cellular and Molecular Neurobiology.
[70] Brian Kirkpatrick,et al. The NIMH-MATRICS consensus statement on negative symptoms. , 2006, Schizophrenia bulletin.
[71] B. Kirkpatrick,et al. Subdomains within the negative symptoms of schizophrenia: commentary. , 2006, Schizophrenia bulletin.
[72] M. Millan,et al. Dopamine D3 receptor antagonists as therapeutic agents. , 2005, Drug discovery today.
[73] I. Laszlovszky,et al. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats , 2005, Psychopharmacology.
[74] N. Andreasen,et al. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. , 2005, The American journal of psychiatry.
[75] P. Sokoloff,et al. Neuroadaptations to hyperdopaminergia in dopamine D3 receptor-deficient mice. , 2005, Life sciences.
[76] H. Tsukada,et al. N-methyl-d-aspartate antagonists as drug models of schizophrenia: a surprising link to tobacco smoking , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[77] Anissa Abi-Dargham,et al. Do we still believe in the dopamine hypothesis? New data bring new evidence. , 2004, The international journal of neuropsychopharmacology.
[78] D. Javitt,et al. Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis , 2004, Schizophrenia Research.
[79] J. Hagan,et al. Selective Antagonism at Dopamine D3 Receptors Enhances Monoaminergic and Cholinergic Neurotransmission in the Rat Anterior Cingulate Cortex , 2003, Neuropsychopharmacology.
[80] R. Wightman,et al. Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D3 receptors , 2002, Neuroscience.
[81] J. Coyle,et al. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. , 2001, The American journal of psychiatry.
[82] R. Buchanan,et al. A separate disease within the syndrome of schizophrenia. , 2001, Archives of general psychiatry.
[83] F. J. White,et al. Alterations in Dopamine Release But Not Dopamine Autoreceptor Function in Dopamine D3 Receptor Mutant Mice , 1998, The Journal of Neuroscience.
[84] W. Eaton,et al. Ten‐year course of schizophrenia—the Madras longitudinal study , 1994, Acta psychiatrica Scandinavica.
[85] D. Javitt,et al. Amelioration of negative symptoms in schizophrenia by glycine. , 1994, The American journal of psychiatry.
[86] R. Goldman,et al. Validation of the 16-item Negative Symptom Assessment. , 1993, Journal of psychiatric research.
[87] P. Kulhara,et al. Positive and negative subtypes of schizophrenia A follow-up study from India , 1990, Schizophrenia Research.
[88] N. Andreasen. The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations , 1989, British Journal of Psychiatry.
[89] J. Lindenmayer,et al. Negative and positive schizophrenic syndromes after the acute phase: a prospective follow-up. , 1986, Comprehensive psychiatry.
[90] P. Cuijpers,et al. Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. , 2014, The American journal of psychiatry.
[91] R. Salvador,et al. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. , 2014, The British journal of psychiatry : the journal of mental science.
[92] Paul M. Grant,et al. Dysfunctional attitudes and expectancies in deficit syndrome schizophrenia. , 2013, Schizophrenia bulletin.
[93] E. Torrey,et al. Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. , 2012, Clinical schizophrenia & related psychoses.
[94] Alexander L. Miller,et al. Interrater reliability of using brief standardized outcome measures in a community mental health setting. , 2011, Psychiatric Services.
[95] P. Buckley. Prevalence of Negative Symptoms in Outpatients With Schizophrenia Spectrum Disorders Treated With Antipsychotics in Routine Clinical Practice: Findings From the CLAMORS Study , 2011 .
[96] P. Sokoloff,et al. Dopamine and glutamate dysfunctions in schizophrenia: Role of the dopamine D3 receptor , 2009, Neurotoxicity Research.
[97] É. Schmidt,et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15 , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.
[98] H. Häfner,et al. The epidemiology of onset and course of schizophrenia , 2000, European Archives of Psychiatry and Clinical Neuroscience.
[99] S. Kay,et al. The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.
[100] M. Harrow,et al. Negative symptoms in schizophrenia: their longitudinal course and prognostic importance. , 1985, Schizophrenia bulletin.